200 related articles for article (PubMed ID: 31727677)
1. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
[TBL] [Abstract][Full Text] [Related]
2. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
3. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.
Renfrow JJ; Soike MH; West JL; Ramkissoon SH; Metheny-Barlow L; Mott RT; Kittel CA; D'Agostino RB; Tatter SB; Laxton AW; Frenkel MB; Hawkins GA; Herpai D; Sanders S; Sarkaria JN; Lesser GJ; Debinski W; Strowd RE
Sci Rep; 2020 Sep; 10(1):15195. PubMed ID: 32938997
[TBL] [Abstract][Full Text] [Related]
4. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Jonasch E; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Dror Michaelson M; Appleman LJ; Roy A; Perini RF; Liu Y; Choueiri TK
Eur J Cancer; 2024 Jan; 196():113434. PubMed ID: 38008031
[TBL] [Abstract][Full Text] [Related]
5. Targeting the HIF2-VEGF axis in renal cell carcinoma.
Choueiri TK; Kaelin WG
Nat Med; 2020 Oct; 26(10):1519-1530. PubMed ID: 33020645
[TBL] [Abstract][Full Text] [Related]
6. Marked and rapid effects of pharmacological HIF-2α antagonism on hypoxic ventilatory control.
Cheng X; Prange-Barczynska M; Fielding JW; Zhang M; Burrell AL; Lima JD; Eckardt L; Argles I; Pugh CW; Buckler KJ; Robbins PA; Hodson EJ; Bruick RK; Collinson LM; Rastinejad F; Bishop T; Ratcliffe PJ
J Clin Invest; 2020 May; 130(5):2237-2251. PubMed ID: 31999648
[TBL] [Abstract][Full Text] [Related]
7. From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer.
Chung C
Am J Health Syst Pharm; 2020 Dec; 77(24):2064-2073. PubMed ID: 33016992
[TBL] [Abstract][Full Text] [Related]
8. HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice.
Hoefflin R; Harlander S; Schäfer S; Metzger P; Kuo F; Schönenberger D; Adlesic M; Peighambari A; Seidel P; Chen CY; Consenza-Contreras M; Jud A; Lahrmann B; Grabe N; Heide D; Uhl FM; Chan TA; Duyster J; Zeiser R; Schell C; Heikenwalder M; Schilling O; Hakimi AA; Boerries M; Frew IJ
Nat Commun; 2020 Aug; 11(1):4111. PubMed ID: 32807776
[TBL] [Abstract][Full Text] [Related]
9. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Rivera DR; Peters S; Panagiotou OA; Shah DP; Kuderer NM; Hsu CY; Rubinstein SM; Lee BJ; Choueiri TK; de Lima Lopes G; Grivas P; Painter CA; Rini BI; Thompson MA; Arcobello J; Bakouny Z; Doroshow DB; Egan PC; Farmakiotis D; Fecher LA; Friese CR; Galsky MD; Goel S; Gupta S; Halfdanarson TR; Halmos B; Hawley JE; Khaki AR; Lemmon CA; Mishra S; Olszewski AJ; Pennell NA; Puc MM; Revankar SG; Schapira L; Schmidt A; Schwartz GK; Shah SA; Wu JT; Xie Z; Yeh AC; Zhu H; Shyr Y; Lyman GH; Warner JL;
Cancer Discov; 2020 Oct; 10(10):1514-1527. PubMed ID: 32699031
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic tropism of metastatic renal cell carcinoma.
Singla N; Xie Z; Zhang Z; Gao M; Yousuf Q; Onabolu O; McKenzie T; Tcheuyap VT; Ma Y; Choi J; McKay R; Christie A; Torras OR; Bowman IA; Margulis V; Pedrosa I; Przybycin C; Wang T; Kapur P; Rini B; Brugarolas J
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271170
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases.
Ghosh MC; Zhang DL; Ollivierre WH; Noguchi A; Springer DA; Linehan WM; Rouault TA
Blood; 2021 May; 137(18):2509-2519. PubMed ID: 33512384
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
[TBL] [Abstract][Full Text] [Related]
13. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016-2020).
Ban HS; Uto Y; Nakamura H
Expert Opin Ther Pat; 2021 May; 31(5):387-397. PubMed ID: 33455469
[No Abstract] [Full Text] [Related]
15. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
[TBL] [Abstract][Full Text] [Related]
16. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
[TBL] [Abstract][Full Text] [Related]
17. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
18. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
Liu XD; Kong W; Peterson CB; McGrail DJ; Hoang A; Zhang X; Lam T; Pilie PG; Zhu H; Beckermann KE; Haake SM; Isgandrova S; Martinez-Moczygemba M; Sahni N; Tannir NM; Lin SY; Rathmell WK; Jonasch E
Nat Commun; 2020 May; 11(1):2135. PubMed ID: 32358509
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
Deleuze A; Saout J; Dugay F; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Crouzet L; Laguerre B; Belaud-Rotureau MA; Rioux-Leclercq N; Kammerer-Jacquet SF
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260578
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
